SS Rats Research Articles

Divergence of Chemerin Reduction by an ATS9R Nanoparticle Targeting Adipose Tissue In Vitro vs. In Vivo in the Rat.

Nanoparticles (NPs) can enable delivery of a drug to a targeted tissue. Previous studies have shown that an NP utilizing an adipose targeting sequence (ATS) peptide in conjunction with a drug can selectively deliver the drug to mouse adipose tissues, using the prohibitin protein expressed in adipose tissue as the target of the ATS. Adipose tissue is a major source of the adipokine chemerin, a prohypertensive protein. Liver-derived chemerin, the largest source of circulating chemerin, is biologically inactive in blood pressure regulation. Our goal is to understand if chemerin produced in adipose tissue contributes to blood pressure/hypertension. We hypothesize the ATS drug delivery system could be used specifically to reduce the levels of adipose tissue-derived chemerin. We created an NP consisting of an antisense oligonucleotide (ASO) against chemerin and a FITC-labeled ATS with a nine arginine sequence (ATS9R). In vitro studies showed that the ASO is functional when incorporated into an NP with ATS9R as it reduced chemerin mRNA expression in isolated epidydimal (Epi) and retroperitoneal (RP) fat adipocytes from Dahl SS rats. This same NP reduced chemerin in isolated whole fats. However, this NP was unable to selectively deliver the ASO to adipose tissue in vivo; liver delivery was dominant. Varying NP doses, administration route, and the concentration of components constituting the NP showed no improvement in ASO delivery to fats vs. the liver. Further studies are therefore needed to develop the ATS9R system to deliver an ASO to adipose beds in rats.

First Author Spotlight

AnnouncementFirst Author SpotlightPublished Online:07 Jun 2022https://doi.org/10.1152/ajprenal.2022.322.6.AUMoreSectionsPDF (247 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat MADELINE GAUTHIERDepartment of Physiology, University of Arizona Health Sciences Center, Tucson, ArizonaFigure 1.Madeline GauthierDownload figureDownload PowerPointMadeline Gauthier is an MD student and PhD candidate, conducting a PhD while on a leave of absence from medical school at Loyola University Chicago. She is currently completing her PhD in the Physiological Sciences Graduate Interdisciplinary Program at the University of Arizona [Photo: Fig. 1].https://doi.org/10.1152/ajprenal.00009.2022OLHA KRAVTSOVADepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FloridaFigure 2.Olha KravtsovaDownload figureDownload PowerPointOlha Kravtsova is a postdoctoral fellow in Dr. Alexander Staruschenko’s laboratory at the University of South Florida in the Department of Molecular Pharmacology and Physiology. She earned her PhD degree at the Institute of Hydrobiology, Kyiv, Ukraine. Her current research focuses on renal transporters, specifically in the proximal tubule. Outside of work, she enjoys workouts, traveling, and hiking [Photo: Fig. 2].https://doi.org/10.1152/ajprenal.00053.2022This article has no references to display. Download PDF Back to Top Next FiguresReferencesRelatedInformation Collections Related ArticlesSGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats 16 May 2022American Journal of Physiology-Renal PhysiologyContributions of afferent and sympathetic renal nerves to cystogenesis and arterial pressure regulation in a preclinical model of autosomal recessive polycystic kidney disease 16 May 2022American Journal of Physiology-Renal Physiology More from this issue > Volume 322Issue 6June 2022Pages i-i Crossmark Copyright & PermissionsCopyright © 2022 the American Physiological Society.https://doi.org/10.1152/ajprenal.2022.322.6.AUHistory Received 2 November 2021 Accepted 30 March 2022 Published online 7 June 2022 Published in print 1 June 2022 Metrics

Treatment with rapamycin reduces progressive proteinuria while inducing hyperglycemia in obese Dahl salt‐sensitive leptin‐receptor mutant rats prior to puberty

Prepubertal obesity (PPO) is now considered a risk factor for the development of proteinuria and renal injury in children. Recently, we observed the early development of renal injury in the obese SSLepRmutant strain is associated with elevations in GFR and glomerular injury prior to puberty. However, the mechanisms involved remain unclear. The mammalian target of rapamycin (mTOR) signaling pathway has been shown to contribute to various forms of renal disease. In the current study, we examined whether treatment with the mTOR inhibitor, rapamycin, reduces the early progression of renal injury in SSLepRmutant rats during PPO. Four week‐old SS and SSLepRmutant rats were treated with either vehicle (saline) or rapamycin (1.5 mg/kg/day, ip) until rats reached 8 weeks of age. At baseline, body weight was significantly higher in vehicle‐treated SSLepRmutant rats compared to SS rats and remained elevated over the course of the study (309±13 vs. 219±27 g, respectively). Treatment with rapamycin significantly reduced body weight in SSLepRmutant rats compared to vehicle SSLepRmutant rats (206±9 g). At baseline, non‐fasting blood glucose levels were similar in both SS and SSLepRmutant rats and were within normal physiological range (≤120 mg/dl). Interestingly, chronic treatment with rapamycin markedly increased blood glucose levels in SSLepRmutant rats vs. vehicle SSLepRmutant rats (438±8 vs. 123±5 mg/dl, respectively) but had no effects in SS rats. At the end of the study, plasma insulin levels were significantly elevated in vehicle‐treated SSLepRmutant rats compared to the values measured in SS rats (6±1 vs. 1±0.6 ng/dl, respectively), and rapamycin treatment only reduced plasma insulin in SSLepRmutant (2±0.7 ng/dl, respectively). At baseline, proteinuria was significantly higher in SSLepRmutant rats compared to SS rats (159±34 and 17±7 mg/day, respectively) and remained elevated throughout the study (558±79 and 73±34 mg/day, respectively). By the end of the study, rapamycin significantly reduced proteinuria in SSLepRmutant rats (225±67 mg/day). We observed a significant increase in creatinine clearance (CCr) in SSLepRmutant rats vs SS rats indicating increased GFR (4.0±0.6 vs. 0.9±0.1 ml/min, respectively). Chronic treatment with rapamycin significantly decreased CCr in SSLepRmutant rats (2.2±0.9 ml/min) while not affecting SS rats. Overall, these data suggest that treatment with rapamycin is effective in reducing progressive proteinuria via reducing GFR while reducing plasma insulin levels and contributing to hyperglycemia in obese SSLepRmutant rats.

Decreasing Insulin Resistance Reduces Early Progressive Proteinuria by Decreasing Renal Hyperfiltration and Inflammation in Obese Dahl Salt‐Sensitive Rats

Prepubertal/childhood obesity (PPO) is quickly becoming an epidemic and is considered a major risk factor for proteinuria. Previous studies have demonstrated that insulin resistance alters renal hemodynamics leading to inflammation and renal injury in obese adults. However, studies examining the relationship between insulin resistance and renal hyperfiltration (RH) and inflammation in obese children are lacking. Recently, we reported that insulin resistance in the obese Dahl salt‐sensitive leptin receptor mutant (SSLepRmutant) rat is associated with progressive proteinuria and RH prior to puberty. Therefore, the aim of the present study was to examine whether decreasing insulin resistance with metformin will reduce proteinuria in SSLepRmutant rats. Four‐week‐old SS and SSLepRmutant rats were separated into 4 groups (n=5/group) and treated with either vehicle (PBS) or metformin (300 mg/kg/day, ip) for 4 weeks. Blood glucose levels were similar among the groups throughout the study (≤ 120 mg/dL). However, at the end of study, plasma insulin levels were significantly elevated in SSLepRmutant rats vs SS rats (9±2 vs 1±0.2 ng/ml respectively; p<0.05), and glucose tolerance was significantly impaired in SSLepRmutant rats compared to values measured in SS rats. Chronic treatment with metformin markedly reduced plasma insulin (2±1 ng/ml; p<0.05) and improved glucose tolerance in SSLepRmutant rats. At baseline, proteinuria was significantly higher in SSLepRmutant rats vs SS rats and remained elevated throughout the study (449±123 vs 25±7 mg/day, respectively; p<0.05). Metformin treatment significantly decreased proteinuria in SSLepRmutant rats (177±80 mg/day; p<0.05) with no effect in SS rats (36±13 mg/day). We observed a significant increase in creatinine clearance (CCr) in SSLepRmutant rats vs SS rats indicating RH (3.3±0.4 ml/min vs 1.9±0.1 ml/min, respectively; p<0.05). Chronic treatment with metformin significantly decreased CCr in SSLepRmutant rats (1.3±0.2 ml/min; p<0.05) while not affecting SS rats. Renal histology revealed marked glomerular injury in vehicle‐treated SSLepRmutant compared to SS rats, and treatment with metformin reduced glomerular injury in SSLepRmutant rats. We observed a significant increase in the renal infiltration of stimulatory dendritic cells and macrophages in vehicle‐treated SSLepRmutant rats compared to their SS counterparts, and metformin reduced the infiltration of these immune cells only in SSLepRmutant rats. MIP3α (pro‐inflammatory cytokine) was significantly increased and IL‐4 (anti‐inflammatory cytokine) was markedly decreased in the kidneys of SSLepRmutant rats compared to their SS counterparts (23±3 vs 5±1 ng/mg and 11±2 vs 54±5 ng/mg, respectively; p<0.05). Treatment with metformin decreased renal MIP3α (10±2 ng/mg; p<0.05), while increasing renal IL‐4 (26±5 ng/mg) in SSLepRmutant rats. These data suggest that decreasing insulin resistance reduces RH, proteinuria, and inflammation and may be therapeutically useful in managing renal injury during PPO.

SPAK‐Independent NKCC2 Phosphorylation in Dahl SS Rats: A Role for TNIK in NKCC2 Hyperphosphorylation

Increased NaCl reabsorption in the Thick Ascending Limb (TAL) is implicated in salt sensitive hypertension. NaCl reabsorption by the TAL is mediated by the apical Na/K/2Cl cotransporter NKCC2. We reported that NKCC2 phosphorylation at Tre 96,101 and surface expression are enhanced in Dahl Salt sensitive rats (Dahl SS) on normal or high salt diets. The phosphorylation of SPS1‐related proline/alanine‐rich kinase (SPAK), an upstream kinase for Thre 96,101 in NKCC2, was found to be higher in Dahl SS TALs. Deletion of SPAK in Dahl SS, lowers NKCC2 phosphorylation and expression and blunts salt‐sensitive hypertension, but does not completely prevent this. Other kinases may be involved in NKCC2 phosphorylation. Using a targeted proteomics approach, we identified TNIK (Traf2 and NCK interacting kinase) as a kinase that binds and phosphorylates Thre 96,101 in NKCC2. We hypothesize that TNIK is in part responsible for enhanced NKCC2 phosphorylation in Dahl SS rats. We first measured total expression of SPAK, OSR1 and TNIK by Western blot in TALs isolated form Dahl SS and control rats. SPAK and OSR1 expression (normalized to GAPDH) was similar between strains whereas TNIK expression was 3‐fold higher in Dahl SS TALs (control: 100, Dahl SS: 396±80%, n =5, p<.025). We then tested whether a novel TNIK inhibitor (KY‐05009) decreased NKCC2 phosphorylation in Dahl SS rats. Treating TALs from Dahl SS with KY‐05009 (1 µM) for 25 min decreased NKCC2 Thre 96,101 phosphorylation by 40±4% (p<0.05, n=5). To study whether NKCC2 phosphorylation can be stimulated in the absence of SPAK, we used SPAK knockout Dahl SS rats. Baseline NKCC2 expression and phosphorylation in TALs was 50% lower in Dahl SS‐SPAK KO TALs, however, stimulation of Beta‐adrenergic receptors with Isoproterenol increased NKCC2 phosphorylation by 192±49% (p<0.01, n =4) in SPAK‐KO. Similarly, the cAMP analogue db‐cAMP (500 µM) increased NKCC2 phosphorylation by 939±183% in SPAK KO (p<0.01 n=4) and by 497±105% (p<0.01 n=4) in control rat TALs, indicating that a kinase other than SPAK is essential for baseline and cAMP‐stimulated NKCC2 phosphorylation in Dahl SS rats. We conclude that enhanced NKCC2 phosphorylation at baseline in Dahl SS TALs is in part caused by TNIK, which show 3‐fold higher expression in this strain. SPAK also contributes to higher baseline NKCC2 phosphorylation, whereas a kinase other than SPAK (either TNIK or OSR1) is involved in cAMP‐stimulated NKCC2 Thre 96,101 phosphorylation in Dahl SS TALs.

Proximal Tubule‐Specific Transgenic Overexpression of Peroxisome Proliferator‐Activated Receptor Alpha Prevents the Development of Hypertension in Dahl Salt‐Sensitive Rats

The Dahl salt‐sensitive rat (Dahl SS) is a well investigated model of hypertension that mimics human salt sensitive hypertension. These rats develop a significant increase in blood pressure and renal disease when challenged with a high salt diet compared to salt‐resistant strains. Prolonged high salt feeding results in extensive renal pathology, including glomerular and proximal tubular pathology, tubular casting, and interstitial fibrosis. It has been shown that clofibrate, a lipid lowering peroxisome proliferator‐activated receptor alpha (PPARα) agonist, can prevent the hypertensive phenotype in Dahl SS rats. PPARα is a ligand activated transcription factor that regulates β‐oxidation of fatty acids (FAO). The proximal tubule is a very metabolically active tubular segment that relies primarily on FAO to meet its high energy requirements. Reduced FAO can lead to proximal tubular damage and renal dysfunction. To investigate the impact of PPARα‐mediated FAO during a high‐salt challenge, we developed a novel transgenic Dahl SS strain with a proximal tubule‐specific promoter from the sodium/glucose cotransporter 2 gene (Sglt2). This resulted in the overexpression of Ppara only in the proximal tubule (SSTgPTPpara). At 9 weeks of age, male wild‐type rats and heterozygous transgenic SSTgPTPpara rats were placed on a 4.0% NaCl, high salt diet (n=6/group). Following a 14‐day high salt challenge, rats were anesthetized for carotid blood pressure recording. Proximal tubule‐specific transgenic overexpression of PPARα in heterozygous SSTgPTPpararats had lower systolic blood pressure when compared to wild‐type littermates (161.2.6 ± 12.0 mmHg vs.122.8 ± 4.2 mmHg; mean ± SEM; p <0.05, t‐test), as well as mean arterial pressure and diastolic blood pressure. Immunohistochemical analysis confirmed an increase in PPARA protein within proximal tubules of the renal cortex, relative to other nephron segments. In conclusion, proximal tubule specific‐transgenic overexpression of PPARα reduced salt‐sensitive hypertension, suggesting that proximal tubules may be one of the primary sites of anti‐hypertensive actions of clofibrate in Dahl SS rats. This also indicates that the SSTgPTPpara rat model could be useful for studying the contribution of dysregulated proximal tubule metabolism to salt‐sensitive hypertension and renal pathology in the Dahl SS rat.

Targeting Adipose Tissues with ATS9R Nanoparticles for Drug Delivery

Nanoparticles (NPs) are a drug delivery system that can enable delivery of a drug to a targeted tissue. Previous studies have shown that the use of an adipose targeting sequence (ATS) peptide in conjunction with a drug in the form of a NP has the ability to selectively deliver the drug to mouse adipose tissues. The prohibitin protein located in adipose tissue is the target of ATS. Adipose tissue is a major source of the adipokine chemerin, a prohypertensive protein. Our laboratory has proven that liver derived chemerin, the largest source of circulating chemerin, is biologically inactive. Our goal is to understand if chemerin produced by adipose tissue contributes to hypertension. We hypothesize an ATS drug delivery system could be applied in rats to specifically reduce the levels of adipose tissue associated chemerin. We created a NP consisting of an antisense oligonucleotide (ASO) against chemerin and a FITC labeled ATS with 9 arginine sequence (ATS9R). In vitro studies showed that the ASO is functional when incorporated into NPs with ATS9R as it reduced chemerin mRNA expression in isolated epidydimal (Epi) adipocytes by 43‐fold compared to vehicle incubated cells (Veh mean 2‐ΔCT=0.039 ± 0.007; NP mean 2‐ΔCT=0.0009 ± 0.0001), and 13‐fold in isolated retroperitoneal (RP) adipocytes (Veh mean 2‐ΔCT=0.041 ± 0.007; NP mean 2‐ΔCT=0.0031 ± 0.0009) of Dahl SS rats. Ex vivo studies support the ability of the ATS9R‐ASO NP to reduce chemerin mRNA expression in tissues. In Epi fat incubated with the NP overnight at 37 oC, chemerin expression was reduced by 2.7‐fold (p<0.05) (Veh mean 2‐ΔCT=0.213 ± 0.088; NP mean 2‐ΔCT=0.079 ± 0.013). The NP also reduced chemerin expression in RP fat by 2.1‐fold (Veh mean 2‐ΔCT=0.159 ± 0.027; NP mean 2‐ΔCT=0.071 ± 0.011), although the changes did not reach statistical significance. However, this same NP was unable to deliver the ASO selectively to adipose tissue in vivo. Two days after subcutaneous injections in Dahl SS rats, the NP caused a significant (p<0.05) 2.4‐fold reduction in liver chemerin mRNA expression compared to vehicle treated animals (Veh 2‐ΔCT=0.753; NP mean 2‐ΔCT=0.311 ± 0.007), but not in Epi (1.8‐fold reduction; Veh 2‐ΔCT=0.175; NP mean 2‐ΔCT=0.095 ± 0.013) or RP fat (1.9‐fold reduction; Veh 2‐ΔCT=0.120; NP mean 2‐ΔCT=0.061 ± 0.015). Varying NP dose, administration route, and concentration of the components constituting the NP did not show any improvement in ASO delivery to fats vs liver. Further studies are needed to develop the ATS9R system to deliver ASO to adipose tissue beds in rats.

Paraoxonase-1 Regulation of Renal Inflammation and Fibrosis in Chronic Kidney Disease.

Papraoxonase-1 (PON1) is a hydrolytic lactonase enzyme that is synthesized in the liver and circulates attached to high-density lipoproteins (HDL). Clinical studies have demonstrated an association between diminished PON-1 and the progression of chronic kidney disease (CKD). However, whether decreased PON-1 is mechanistically linked to renal injury is unknown. We tested the hypothesis that the absence of PON-1 is mechanistically linked to the progression of renal inflammation and injury in CKD. Experiments were performed on control Dahl salt-sensitive rats (SSMcwi, hereafter designated SS rats) and Pon1 knock-out rats (designated SS-Pon1em1Mcwi, hereafter designated SS-PON-1 KO rats) generated by injecting a CRISPR targeting the sequence into SSMcwi rat embryos. The resulting mutation is a 7 bp frameshift insertion in exon 4 of the PON-1 gene. First, to examine the renal protective role of PON-1 in settings of CKD, ten-week-old, age-matched male rats were maintained on a high-salt diet (8% NaCl) for up to 5 weeks to initiate the salt-sensitive hypertensive renal disease characteristic of this model. We found that SS-PON-1 KO rats demonstrated several hallmarks of increased renal injury vs. SS rats including increased renal fibrosis, sclerosis, and tubular injury. SS-PON-1 KO also demonstrated increased recruitment of immune cells in the renal interstitium, as well as increased expression of inflammatory genes compared to SS rats (all p < 0.05). SS-PON-1 KO rats also showed a significant (p < 0.05) decline in renal function and increased renal oxidative stress compared to SS rats, despite no differences in blood pressure between the two groups. These findings suggest a new role for PON-1 in regulating renal inflammation and fibrosis in the setting of chronic renal disease independent of blood pressure.

SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats.

Na+-glucose cotransporter-2 (SGLT2) inhibitors are the new mainstay of treatment for diabetes mellitus and cardiovascular diseases. Despite the remarkable benefits, the molecular mechanisms mediating the effects of SGLT2 inhibitors on water and electrolyte balance are incompletely understood. The goal of this study was to determine whether SGLT2 inhibition alters blood pressure and kidney function via affecting the renin-angiotensin-aldosterone system (RAAS) and Na+ channels/transporters along the nephron in Dahl salt-sensitive rats, a model of salt-induced hypertension. Administration of dapagliflozin (Dapa) at 2 mg/kg/day via drinking water for 3 wk blunted the development of salt-induced hypertension as evidenced by lower blood pressure and a left shift of the pressure natriuresis curve. Urinary flow rate, glucose excretion, and Na+- and Cl--to-creatinine ratios increased in Dapa-treated compared with vehicle-treated rats. To define the contribution of the RAAS, we measured various hormones. Despite apparent effects on Na+- and Cl--to-creatinine ratios, Dapa treatment did not affect RAAS metabolites. Subsequently, we assessed the effects of Dapa on renal Na+ channels and transporters using RT-PCR, Western blot analysis, and patch clamp. Neither mRNA nor protein expression levels of renal transporters (SGLT2, Na+/H+ exchanger isoform 3, Na+-K+-2Cl- cotransporter 2, Na+-Cl- cotransporter, and α-, β-, and γ-epithelial Na+ channel subunits) changed significantly between groups. Furthermore, electrophysiological experiments did not reveal any difference in Dapa treatment on the conductance and activity of epithelial Na+ channels. Our data suggest that SGLT2 inhibition in a nondiabetic model of salt-sensitive hypertension blunts the development of salt-induced hypertension by causing glucosuria and natriuresis without changes in the RAAS or the expression or activity of the main Na+ channels and transporters.NEW & NOTEWORTHY The present study indicates that Na+-glucose cotransporter-2 (SGLT2) inhibition in a nondiabetic model of salt-sensitive hypertension blunts the development and magnitude of salt-induced hypertension. Chronic inhibition of SGLT2 increases glucose and Na+ excretion without secondary effects on the expression and function of other Na+ transporters and channels along the nephron and hormone levels in the renin-angiotensin-aldosterone system. These data provide novel insights into the effects of SGLT2 inhibitors and their potential use in hypertension.

The SSLepR mutant rat represents a novel model to study obesity-induced renal injury before puberty.

Prepubertal obesity (PPO) has emerged as a major health problem over the past few decades and is a risk factor for the development of proteinuria. The current study investigated whether the development of renal injury in the obese SSLepR mutant strain occurs before puberty. When determining the temporal changes in serum sex hormones in female and male SS and SSLepR mutant rats between 4 and 10 wk of age, we only observed significant increases in estradiol and testosterone levels in female and male SS rats at 10 wk of age than at 4 wk of age. The results suggest that studying both strains between 4 and 8 wk of age is appropriate to study the effects of PPO on renal injury in this model. Proteinuria was significantly higher in SSLepR mutant rats as opposed to the values observed in SS rats at 8 wk of age, and we did not observe any sex differences in proteinuria in either strain. The kidneys from the SSLepR mutant rats displayed significant glomerular and tubular injury and renal fibrosis versus the values measured in SS rats without any sex differences. Overall, we observed increased immune cell infiltration in the kidneys from SSLepR mutant rats compared with SS rats. Interestingly, female SSLepR mutant rats displayed significant increases in not only M1 macrophages (proinflammatory) but also M2 macrophages (anti-inflammatory) versus male SSLepR mutant rats. These results suggest the SSLepR mutant rat may be a useful model to study early progression of obesity-related renal injury before the onset of puberty.

Treatment With Lisinopril Prevents the Early Progression of Glomerular Injury in Obese Dahl Salt-Sensitive Rats Independent of Lowering Arterial Pressure.

Recently, we reported that obese Dahl salt-sensitive leptin receptor mutant (SSLepRmutant) rats develop glomerular injury and progressive proteinuria prior to puberty. Moreover, this early progression of proteinuria was associated with elevations in GFR. Therefore, the current study examined whether treatment with lisinopril to reduce GFR slows the early progression of proteinuria in SSLepRmutant rats prior to puberty. Experiments were performed on 4-week-old SS and SSLepRmutant rats that were either treated with vehicle or lisinopril (20 mg/kg/day, drinking water) for 4 weeks. We did not observe any differences in MAP between SS and SSLepRmutant rats treated with vehicle (148 ± 5 vs. 163 ± 6 mmHg, respectively). Interestingly, chronic treatment with lisinopril markedly reduced MAP in SS rats (111 ± 3 mmHg) but had no effect on MAP in SSLepRmutant rats (155 ± 4 mmHg). Treatment with lisinopril significantly reduced proteinuria in SS and SSLepRmutant rats compared to their vehicle counterparts (19 ± 5 and 258 ± 34 vs. 71 ± 12 and 498 ± 66 mg/day, respectively). Additionally, nephrin excretion was significantly elevated in SSLepRmutant rats versus SS rats, and lisinopril reduced nephrin excretion in both strains. GFR was significantly elevated in SSLepRmutant rats compared to SS rats, and lisinopril treatment reduced GFR in SSLepRmutant rats by 30%. The kidneys from SSLepRmutant rats displayed glomerular injury with increased mesangial expansion and renal inflammation versus SS rats. Chronic treatment with lisinopril significantly decreased glomerular injury and renal inflammation in the SSLepRmutant rats. Overall, these data indicate that inhibiting renal hyperfiltration associated with obesity is beneficial in slowing the early development of glomerular injury and renal inflammation.

Abstract 13166: Paraoxonase-3 Regulation of Cardiotonic Steroids Mediates Renal Injury and Dysfunction in a Dahl Salt Sensitive Model of Chronic Kidney Disease

Background: Paraoxonases (Pons) belong to a family of hydrolytic enzymes with 3 distinct isoforms: Pon 1, 2, and 3. While the physiologic substrates for Pons are unclear, their lactonase activity is considered central to their native physiological role. We have previously demonstrated an association between diminished Pon lactonase activity and worse clinical outcomes in volume expanded states such as chronic kidney disease (CKD). Furthermore, we have identified a novel reno-protective role for Pon3 in hypertensive renal disease. However, the underlying mechanism(s) are unknown. Cardiotonic steroids (CTS) are natriuretic hormones that are increased in CKD and promote renal inflammation and fibrosis via binding of their 17β-lactone ring to the alpha-1 subunit of the Na + /K + -ATPase (NKA-α-1). Therefore, we tested the hypothesis that reduction of Pon3 lactonase activity would lead to increased renal injury and dysfunction in a CTS induced rat model of CKD. Methods/Results: Experiments were performed on Dahl salt-sensitive rats (SS rats) and Pon3 knock-out rats on the Dahl salt-sensitive background (SS- Pon3 KO). First, CTS levels in the urine of SS control and SS- Pon3 KO rats were quantified using mass spectrometry. We found that SS- Pon3 KO rats had 59 times greater increase in 24-hour urine CTS levels vs SS rats. Next, to examine the role of Pon3 in mediating CTS induced renal injury, ten-week-old, age-matched male SS control and SS- Pon3 KO rats were administered the CTS telocinobufagin (TCB, 100 μg/kg/day s.q) for four weeks followed by assessment of blood pressure (tail cuff plethysmography) and renal function. We found that SS- Pon3 KO rats following TCB administration had significantly increased 24-hour urinary protein excretion (UPE) (50.73 ± 3.59vs 25.29 ± 2.07, p&lt;0.0001), as well as decreased FITC-Sinistrin monitored glomerular filtration rate (GFR) (0.80 ± 0.10 vs 1.16 ± 0.05, p&lt;0.01) compared to SS control rats, despite similar degrees of hypertension. Conclusion: These findings suggest that Pon3 plays a critical role in regulating CTS mediated renal dysfunction in vivo.

Social Instability Stress in Adolescence and Social Interaction in Female Rats

Adolescence is a critical time of brain development for regions governing social behaviour and social learning. Social experiences influence the ongoing maturation of the neural structures and ultimately modify the social behaviour of adults in response to social cues. Social instability stress in adolescence (SS; daily 1-hour isolation + change of cage partner in postnatal days [PND] 30–45) leads to a long-lasting reduction in social interaction in SS rats compared with non-stressed (CTL) rats in males; here we investigate females. In a first experiment, we found that female rats exposed to adolescent SS also showed the decrement in social interaction irrespective of age at which tested, and replicated the effects previously found in males. In experiment 2, which involved females only, SS and CTL rats did not differ in anxiety-like behaviour in the elevated plus maze (EPM) and the reduction in social interaction was not significant. Nevertheless, when tested in adolescence at P47 (and not at P71), SS female rats had higher corticosterone release during the social interaction test than did CTL rats, and they exhibited a different pattern of neural activation as measured by immunoreactivity to the protein products of zif268 and c-fos (SS < CTL in medial prefrontal cortex and SS > CTL in hippocampus), and reduced oxytocin immunoreactivity in the paraventricular nucleus of the hypothalamus than did CTL rats. These results extend our previous findings of effects of SS in adolescent female rats on behavioural responses to psychostimulants to social behaviour, and point to directions for investigations of the neural mechanisms involved.

Abstract 42: Inhibiting Stimulatory Dendritic Cells Reduces Early Progressive Proteinuria In Obese Dahl Salt-sensitive Rats.

Childhood/prepubertal (PPO) obesity has emerged as an epidemic and major health problem over the last few decades and is a risk factor for the development of proteinuria. With the rising prevalence of obesity in children, studies examining how obesity contributes to the early development of proteinuria and renal injury in children are lacking. Recently, we observed that the early progression of proteinuria in the obese SS LepR mutant rats was associated with the increased renal infiltration of stimulatory dendritic cells (sDCs). Previous studies have demonstrated that sDCs interact with and activate T-cells to elicit a pro-inflammatory response. Therefore, the current study examined whether chronic treatment with abatacept will reduce proteinuria in SS LepR mutant rats prior to puberty by interfering with sDC-T-cell crosstalk. Four-week-old SS and SS LepR mutant rats were treated with either vehicle (PBS) or abatacept (1 mg/kg, i.p. every alternate day) for 4 weeks. We observed no significant differences in blood glucose levels and mean arterial pressure between vehicle- and abatacept-treated SS and SS LepR mutant rats. While proteinuria only rose from 9±3 to 48±28 mg/day in SS rats, proteinuria markedly increased from 40±13 to 638±73 mg/day in SS LepR mutant rats. Chronic treatment with abatacept significantly decreased the progression of proteinuria by almost 50% in SS LepR mutant rats (350±15 mg/day; p&lt;0.05 vs. vehicle-treated SS LepR mutant rats) without having any effect in SS rats (29±11 mg/day). We observed a significant increase in the renal infiltration of sDCs and cytotoxic T-cells in SS LepR mutant rats in comparison to their lean SS counterparts, and chronic treatment with abatacept reduced the infiltration of sDCs and cytotoxic T-cells only in the SS LepR mutant rats. These data indicate that targeting sDC/T-cell interaction pathways could offer novel therapeutic insights in the early management of proteinuria and renal injury associated with PPO.

Abstract 41: Changes In Renal Oxygen Consumption With High-salt Diet Differ Between Sprague Dawley And Dahl Salt Sensitive Rats.

It has appeared evident that blood flow to the renal cortex which is required for glomerular filtration far exceeds the delivery of O 2 required for tubular metabolic needs. Yet, the metabolic needs of kidneys are second only to the heart per gram tissue and changes in O 2 extraction and utilization have not been directly measured in face of enhanced workloads such those imposed by high salt (HS) diets. We have developed techniques enabling continuous 24 hr/d monitoring of renal blood flow (RBF; Transonic flow probe) together with blood pressure (BP, 24hr/d) and intermittent sampling of arterial and renal venous blood over 21 days. O 2 content (mL/dL) was determined as 1.31 х Hemoglobin (Hb) (g/dL) х HbO 2 (%) + 0.003 х PaO 2 (mmHg); O 2 consumption (ml/min) was determined as RBF (ml/min) х (arterial-renal venous O 2 content difference). Sprague Dawley rats (SD; n=7; 10 wk age) were compared to Dahl salt-sensitive (SS; n=6; 8 wk age) rats fed 0.4% NaCl and during the 21 days of 4.0% NaCl (HS) diet. Beginning 7 days following surgery, RBF and BP were recorded 24 hr/day, and arterial and renal venous blood sampled for determination of blood gases (ABL800 FLEX radiometer) at 7, 14 and 21 of the HS diet. Average 24 hr mean BP of SD rats increased with the HS diet from 111±2 to 119±5 mmHg and SS rats rose from 121±5 to 155±9 mmHg (p&lt;0.05); average 24 hr RBF of SD rats rose from 9.2±0.6 to 11.7 + 0.6 ml/min (p&lt;0.05) while SS rats exhibited little change (7.0±0.6 to 7.0 + 0.9). RBF when expressed per gram kidney weight (gkw; determined in separate groups of rats) remained unchanged in both SD and SS rats in response to the HS diet. SS rats exhibited lower levels of RBF gkw than SD rats (p&lt;0.05). Expressed either as absolute values or gkw, O 2 extraction and consumption was increased significantly in SD rats but not SS rats fed the HS diet. The results of the study indicate that despite high levels of RBF per tissue weight, increased metabolic work imposed by a HS diet resulted in a significant increase of RBF, O 2 extraction and consumption in normal rats. In contrast, SS rats exhibited lower levels of RBF but failed to increase either O 2 delivery or extraction. This failure may contribute importantly to altered metabolic substrate utilization in SS rats fed a HS diet, progression of ischemic related injury and hypertension.

Abstract P283: CCL5 Acts As A Vasoconstrictor On Penetrating Arterioles In The Cerebral Circulation By Enhancing 20-HETE Activity

20-HETE is synthesized from arachidonic acid by cytochrome P450 (CYP) enzymes 4A and 4F. Inactivating mutations in the CYP enzymes that produce 20-HETE are associated with hypertension and stroke in man. We previously revealed that inactivating variants of CYP4A/F enzymes are associated with dementia in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NS) population. 20-HETE is involved with sodium regulation in the kidney and is a powerful vasoconstrictor. It was recently discovered that CCL5 and 20-HETE share the same receptor, GPR75. We previously found that 20-HETE constricts and augments the myogenic response (MR) of the middle cerebral artery (MCA) and renal afferent arteriole. However, whether CCL5 has any effect on penetrating arterioles (PAs) and interacts with 20-HETE is unknown. We found that GPR75 is expressed in PAs and pericytes in the brain. CYP4A is also expressed in pericytes and is inversely proportional to levels of GPR75 in the brain. In the present study, we found that 20-HETE contributes to the basal myogenic tone of PAs in SD rats. Administration of HET0016, a 20-HETE synthesis inhibitor, dilated the PA by 34 ± 3% (n = 6) under 10 mmHg perfusion pressure. Administration of WIT003, a 20-HETE agonist, constricted the vessel by 23 ± 4% (n = 6) under the same perfusion pressure. We found that CCL5 also reduced PA diameter by 20 ± 4% (n = 7) in SD rats under 10 mmHg perfusion pressure. Moreover, we compared the response to CCL5 in SS rats that are 20-HETE deficient and SS.CYP4A1 transgenic rats in which 20-HETE production is restored. PAs isolated from SS rats treated with 0.1 nM CCL5 constricted by 9 ± 5% (n = 6) while those treated with 10 nM constricted by 12 ± 3% (n = 6). CCL5 had a greater response in PAs from the SS.CYP4A1 strain, and the diameter of the PAs constricted by 14 ± 2% (n = 5) and 24 ± 5% (n = 5) in response to 0.1 and 10 nM CCL5, respectively. These results demonstrate that CCL5 has a direct effect on PAs similar to 20-HETE that acts via the GPR75 receptor. However, further study is needed to determine how CCL5 and 20-HETE interact to promote vasoconstriction. These studies would help further understand the involvement of 20-HETE in disease and potentially identify novel drug targets.

Abstract MP06: Insights Into The Role Of Anp In Hfpef During Ss Hypertension

Background: Atrial natriuretic peptide ( ANP) is a hormone produced primarily in the heart, which induces vasodilation and natriuresis. We showed previously that a knockout of ANP in Dahl SS rat results in hypertension and HFpEF phenotype. There is a gap in knowledge regarding the role of inflammation and mitochondrial function in HFpEF that accompanies SSH. We hypothesize that the ANP deficiency in SSH leads to pressure overload, which affects cardiac inflammation and mitochondrial function. Methods: At 8 weeks of age, male wild type (SS WT ) and Nppa knockout (ANP knockout, SS Nppa-/- ) Dahl SS rats were placed on normal salt ( NS , 0.4% NaCl) or a high salt ( HS , 4% NaCl) for 21 days. Tissues were harvested for histological and Western analysis. TEM was used to obtain electron micrographs. EPR spectroscopy was performed in snap-frozen tissues post injection of POBN. 2-way ANOVA was employed for statistical comparison. Results: Heart-to-body-weight ratio was higher in SS Nppa-/- rats (p&lt;0.001), on NS and HS diet ( p &lt;0.001). SS Nppa-/- rats displayed increases in cardiac fibrosis following HS diet ( p &lt;0.01). EPR demonstrated that SS Nppa-/- hearts exhibit a trend for increased lipid peroxidation compared to SS WT . Cardiac cytokine profile demonstrated an increase in IL-1α, IL-1β, L-6, IL-17, TNF-α, sICAM-1, MIP-1α, MIP-3α, in the SS WT rats fed a HS diet vs NS diet, and lower levels of these in the HS-diet fed SS Nppa-/- rats vs SS WT . HS diet was sufficient to induce increases in mitochondrial area ( p &lt;0.001), and decreases in density ( p 0.001), and overall health score ( p &lt;0.001) in both SS WT and SS Nppa-/- rats, but no genotype-specific differences were reported. We observed changes in fission/fusion proteins: Opa1 expression was elevated in SS Nppa-/- vs SS WT ( p &lt;0.01), and Parkin expression was lower in all rats on a HS diet ( p &lt;0.05). Conclusions: Although SS Nppa-/- rats develop a HFpEF phenotype, exacerbated cardiac fibrosis and higher lipid peroxidation vs SS WT rats, inflammation and overall mitochondrial damage are diminished in the hearts of these animals at day 21 of the HS diet. Further studies are needed to elucidate the mechanisms by which inflammation may affect the development of HFpEF during SS hypertension in a cell-specific and time-dependent manner.

Deep transcriptomic profiling of Dahl salt-sensitive rat kidneys with mutant form of Resp18

Expression of Regulated endocrine specific protein 18 (Resp18) is localized in numerous tissues and cell types; however, its exact cellular function is unknown. We previously showed that targeted disruption of the Resp18 locus in the Dahl SS (SS) rat (Resp18mutant) results in higher blood pressure (BP), increased renal fibrosis, increased urinary protein excretion, and decreased mean survival time following a chronic (6 weeks) 2% high salt (HS) diet compared with the SS rat. Based on this prominent renal injury phenotype, we hypothesized that targeted disruption of Resp18 in the SS rat promotes an early onset hypertensive-signaling event through altered signatures of the renal transcriptome in response to HS. To test this hypothesis, both SS and Resp18mutant rats were exposed to a 7-day 2% HS diet and BP was recorded by radiotelemetry. After a 7-day exposure to the HS diet, systolic BP was significantly increased in the Resp18mutant rat compared with the SS rat throughout the circadian cycle. Therefore, we sought to investigate the renal transcriptomic response to HS in the Resp18mutant rat. Using RNA sequencing, Resp18mutant rats showed a differential expression of 25 renal genes, including upregulation of Ren. Upregulation of renal Ren and other differentially expressed genes were confirmed via qRT-PCR. Moreover, circulating renin activity was significantly higher in the Resp18mutant rat compared with the WT SS rat after 7 days on HS. Collectively, these observations demonstrate that disruption of the Resp18 gene in the SS rat is associated with an altered renal transcriptomics signature as an early response to salt load.

Dietary protein source contributes to the risk of developing maternal syndrome in the Dahl salt-sensitive rat.

Preeclampsia (PE) is a disorder of pregnancy, which is categorized by hypertension and proteinuria or signs of end-organ damage. Though PE is the leading cause of maternal and fetal morbidity and mortality, the mechanisms leading to PE remain unclear. The present study examined the contribution of dietary protein source (casein versus wheat gluten) to the risk of developing maternal syndrome utilizing two colonies of Dahl salt-sensitive (SS/JrHsdMcwi) rats. While the only difference between the colonies is the diet, the colonies exhibit profound differences in the pregnancy phenotypes. The SS rats maintained on the wheat gluten (SSWG) chow are protected from developing maternal syndrome; however, approximately half of the SS rats fed a casein-based diet (SSC) exhibit maternal syndrome. Those SSC rats that develop pregnancy-specific increases in blood pressure and proteinuria have no observable differences in renal or placental immune profiles compared to the protected SS rats. A gene profile array of placental tissue revealed a downregulation in Nos3 and Cyp26a1 in the SSC rats that develop maternal syndrome accompanied with increases in uterine artery resistance index suggesting the source of this phenotype could be linked to inadequate remodeling within the placenta. Investigations into the effects of multiple pregnancies on maternal health replicated similar findings. The SSC colony displayed an exacerbation in proteinuria, renal hypertrophy and renal immune cell infiltration associated with an increased mortality rate while the SSWG colony were protected highlighting how dietary protein source could have beneficial effects in PE.

Sex Differences in Macrophage Polarization During the Early Progression of Renal Disease in Obese Dahl Salt‐Sensitive Rats Prior to Puberty

Childhood/prepubertal (PPO) obesity has emerged as an epidemic and major health problem over the last few decades and is a risk factor for the development of proteinuria. Recently, we reported that the development of progressive renal injury in obese female and male Dahl salt-sensitive leptin receptor mutant (SSLepRmutant) rats was associated with increased renal macrophage infiltration as early as 8 weeks of age. The current study investigated whether there are differences in the polarization of infiltrating macrophages in female and male SSLepRmutant rats during the early progression of renal injury (M1; pro-inflammatory and M2; anti-inflammatory). Sex hormones were also monitored to determine if the development of renal injury in SSLepRmutant strain occurs prior to puberty. Female and male lean SS and obese SSLepRmutant rats were studied biweekly from 4 to 10 weeks of age monitoring serum sex hormones and renal injury. Estradiol and testosterone levels were similar in all groups at 4 weeks of age and averaged 11±1 and 0.44±0.15 ng/mL, respectively. The levels of estradiol only significantly increased in female SS rats at 10 weeks of age (24±7 ng/mL; p<0.05 vs 4 weeks of age) and remain unchanged in all other groups. When examining the levels of testosterone in male rats, we observed a marked increase in male SS rats only at 10 weeks of age (2.53±0.69 ng/mL; p<0.05 vs 4 weeks of age), and we did not detect any differences from baseline in the other groups. Proteinuria was significantly higher in female and male SSLepRmutant rats as opposed to the values observed in SS rats at 4 weeks of age (56±7 and 60±13 vs 12±4 and 9±3 mg/day, respectively, n=6). While we observed minimal increases in proteinuria in SS rats at 8 weeks of age, proteinuria increased to 288±45 and 376±44 mg/day in female and male SSLepRmutant rats, respectively. We observed no sex differences in proteinuria in either the SSLepRmutant or SS rats. In support of our previous work, renal macrophage (CD68+) infiltration was significantly higher in the SSLepRmutant rats when compared to their lean counterparts. Interestingly, the female SSLepRmutant rats displayed significantly higher macrophage (CD68+) infiltration than their male counterparts. Moreover, female SSLepRmutant rats displayed significant increases in both macrophage subtypes M1 (CD68+/iNOS+) and M2 (CD68+/CD163+) versus male SSLepRmutant rats as well as SS rats. The male SSLepRmutant rats only displayed significant increases in M1 macrophages (CD68+/iNOS+) compared to male SS rats. The kidneys from the SSLepRmutant rats displayed significant glomerular injury and marked renal fibrosis versus the values measured in SS rats without any sex differences. These data indicate that the SSLepRmutant strain displays sex differences in renal macrophage polarization and develops renal injury prior to the onset of puberty. The SSLepRmutant strain may be considered a useful model to study the early development of renal injury associated with PPO and to understand the underlying mechanisms that contribute to future risk of obesity-related CKD.